Alzheimer's disease drug development is a dynamic area of research marked by persistent challenges and ongoing clinical trials. Efforts primarily center on combating beta-amyloid plaques and tau tangles, the characteristic brain abnormalities in Alzheimer's patients. Potential drugs aim to either reduce beta-amyloid production or enhance its removal from the brain. There's also growing exploration of therapies targeting neuroinflammation, oxidative stress, and synaptic dysfunction, all implicated in disease progression. Despite promising preclinical findings, clinical trials often encounter setbacks, with many drug candidates failing to demonstrate efficacy or safety in human studies. Researchers are also investigating innovative strategies such as genetic therapies and repurposing existing medications. These efforts underscore the urgent global need for effective treatments to alleviate the increasing burden of Alzheimer's and dementia.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Association between APOE allele prevalence and Alzheimer's disease risk in Southwestern Uganda
Frank Balikoowa, African Research Center for Ageing & Dementia, Uganda
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China